Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2024-04-26 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
中信建投证券股份有限公司关于科兴生物制药股份有限公司2023年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导现场检查报告" (2023 Annual Continuous Supervision On-site Inspection Report) issued by the sponsoring institution 中信建投证券股份有限公司 for 科兴生物制药股份有限公司. It details the on-site inspection activities conducted during April 2024, covering company governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, guarantees, investments, and operational status. The document is a detailed report of the inspection findings and opinions, not a general annual report or audit report. It is not an announcement or a brief notice but a substantive report on regulatory continuous supervision. This type of document aligns with the category of Audit Report / Information (AR), as it is a standalone inspection report related to regulatory compliance and internal controls, distinct from a full annual report (10-K) or interim report (IR). The document length is 3710 characters, which is substantive but not overly long, consistent with an audit or inspection report. Therefore, the best classification is AR with high confidence. FY 2023
2024-04-26 Chinese
2023年度独立董事述职报告（唐安）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from a company. It details the independent director's background, attendance at board and committee meetings, oversight activities, opinions on related party transactions, internal control evaluations, and other governance-related matters. It does not contain financial statements or quarterly/annual financial results but focuses on the director's duties and governance oversight for the year. This type of document is a report by a board member on their activities and governance role, which fits best under Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-26 Chinese
2023年度独立董事述职报告（曹红中）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 from a company. It details the independent director's background, attendance at board and committee meetings, oversight activities, opinions on related party transactions, internal control evaluations, and other governance-related matters. It does not contain financial statements or detailed financial data but rather focuses on the director's duties, governance, and compliance with laws and regulations. This type of document is a report by a board member on their duties and governance activities, which fits best under the category of Board/Management Information (MANG). The document length is about 5,035 characters, which is sufficient for a detailed report but it is not an annual report or audit report. Therefore, the classification is MANG with high confidence.
2024-04-26 Chinese
关于首次公开发行股票部分募集资金投资项目延期的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the delay of investment projects funded by proceeds from its initial public offering (IPO). It details the postponement of specific projects, the reasons for the delay, and includes approvals from the board, independent directors, and supervisory board. The document references regulatory approvals and compliance with stock exchange rules. It does not contain financial statements or detailed financial performance data but is a formal disclosure about changes in the use of raised capital and project timelines. The document length is 4087 characters, which is relatively short and focused on a specific announcement rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about the status of capital use and project progress, not a full financial report or earnings release.
2024-04-26 Chinese
关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关事宜的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the board of directors of a company regarding a proposal to authorize the board to issue shares to specific investors via a simplified procedure. It details the terms, conditions, and authorization scope for this share issuance, including pricing, use of proceeds, and regulatory compliance. The document is not a full financial report or earnings release but rather a formal announcement about a capital raising activity. It does not contain financial statements or detailed financial analysis but focuses on the capital issuance process and shareholder authorization. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and is a detailed announcement, not a brief notice or a report publication announcement.
2024-04-26 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2023年度募集资金存放及使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) by the sponsor institution 中信建投证券股份有限公司 regarding the 2023 annual fundraising funds deposit and actual usage of 科兴生物制药股份有限公司. It details the fundraising amount, usage, management, and compliance with regulatory requirements. It includes detailed financial figures about fundraising, usage, and balances, as well as auditor and sponsor opinions on compliance. The document is about the management and use of funds raised in an IPO and subsequent usage, which is a specialized audit or inspection report on fundraising funds. It is not a full annual report (10-K), nor an earnings release, nor a general regulatory filing. It is a standalone audit-related report focusing on fundraising funds usage and compliance, consistent with the definition of an Audit Report / Information (AR). The document length (8460 characters) is sufficient to be the report itself, not just an announcement. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.